Efficacy and tolerability of sulforaphane in the therapeutic management of cancers: a systematic review of randomized controlled trials
ElKhalifa D, Al-Ziftawi N, Awaisu A, Alali F, Khalil A
Frontiers in oncology · 11 citas
Cómo se estudió
- Diseño
- Revisión sistemática (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Eventos clínicos como enfermedad o muerte
- Consumo medido con
- No se indica
Quién lo pagó
- Financiación
- Financiación independiente
- Universidad u hospital
- Qatar University
Según 1 financiador declarado y la declaración de financiación del texto completo.
Publicación
- Publicado
- 2023-11-24 · Front Oncol · vol. 13 · pág. 1251895
- Editorial
- Frontiers Media
- Citado
- 19 citas · más que el 61% de estudios similares · 0.6× el promedio de su campo
- Referencias
- 63 trabajos
- Acceso
- Acceso abierto (revista) · CC-BY
- Áreas de investigación
- Genomics, phytochemicals, and oxidative stress · Curcumin's Biomedical Applications · Kruppel-like factors research
- Palabras clave
- Medicine, Adverse effect, Oncology, Meta-analysis, Prostate cancer, Internal medicine, Cancer, Tolerability, Systematic review, Randomized controlled trial, Clinical trial, Pancreatic cancer, Sulforaphane, MEDLINE, Cancer research
5 autores
- Dana H. Elkhalifa🇶🇦Qatar Orthopaedic and Sports Medicine Hospital
- Nour Hisham Al-Ziftawi
- Ahmed Awaisu🇶🇦Qatar University
- Feras Qasem Alali🇶🇦Qatar University
- Ashraf A. Khalil🇶🇦 · autor de correspondenciaQatar University
Resumen
El texto original del estudio, en el idioma en que se publicó.
Objectives
This paper presents a systematic review aimed at assessing the therapeutic potential of sulforaphane (SFN) in the treatment of diverse cancer types.
Methods
Following Cochrane guidelines for systematic reviews, we conducted an exhaustive search of electronic databases up to May 12, 2023, encompassing PubMed, Cochrane, Embase, Web of Science, Google Scholar, Natural Medicines, ProQuest, ClinicalTrials.gov, and ICTRP. Studies were included if they were human-based RCTs involving cancer patients where SFN was the primary experimental treatment. The Cochrane Risk of Bias tool for RCTs (RoB2) was used for quality assessment.
Results
Eight studies investigating the efficacy and safety of SFN in prostate cancer (PCa), breast cancer, pancreatic cancer, and melanoma were identified and included in the review. The dosing regimens were variable and inconsistent across the studies. SFN treatment led to statistically significant alterations in several vital genes and histological biomarkers across the studies. However, it did not impact some other key genes. Although not statistically significant, SFN improved overall survival in pancreatic cancer patients. The results on prostate-specific antigen (PSA) were inconsistent in PCa. None of the studies reported significant differences between SFN and comparative controls in terms of adverse events.
Conclusion
SFN has emerged as a promising and safe therapeutic agent for diverse cancer types. Nevertheless, the high levels of methodological and clinical heterogeneity across the included studies precluded the possibility of conducting meta-analyses. Further robust clinical investigations to conclusively ascertain the chemotherapeutic potential of SFN in the management of various cancer forms are needed.
Systematic review registration
https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022323788, identifier CRD42022323788.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.